Derudover fik 46 patienter med Ph+ ALL dasatinib 70 mg 2 gange daglig (44 resistente og 2 intolerante over for imatinib).
In addition, 46 patients with Ph+ ALL received dasatinib 70 mg twice daily (44 resistant and 2 intolerant to imatinib).